Curaleaf Holdings (CURLF) Retained Earnings (2019 - 2025)
Curaleaf Holdings (CURLF) posted quarterly Retained Earnings of $2.3 billion for Q4 2025, up 272.94% year-on-year from $628.9 million in Q4 2024, and up 272.94% on a QoQ basis from -$1.4 billion in Q4 2024.
Curaleaf Holdings (CURLF) Retained Earnings (2019 - 2025) Analysis & Trends
Curaleaf Holdings (CURLF) has reported Retained Earnings for 7 consecutive years, with $2.3 billion the latest figure, recorded in Q4 2025.
- Quarterly Retained Earnings rose 272.94% year-over-year to $2.3 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.3 billion (up 272.94% YoY) and the FY2025 annual result came in at $2.3 billion, up 272.94% from the prior year.
- Retained Earnings improved to $2.3 billion in Q4 2025 per CURLF's latest filing, from -$1.4 billion in the prior quarter.
- Over the last five years, Retained Earnings for CURLF reached as high as $2.3 billion in Q4 2025 and fell as low as -$311.4 billion in Q1 2022.
- A 5-year average of -$20.9 billion and a median of -$219.1 million in 2021 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2022 — Retained Earnings plunged 146877.19% — and 2025, when it surged 272.94%.
- Year by year, Retained Earnings stood at -$489.5 million in 2021, then surged by 96.2% to -$18.6 million in 2022, then jumped by 36.14% to -$11.9 million in 2023, then tumbled by 11320.41% to -$1.4 billion in 2024, then jumped by 272.94% to $2.3 billion in 2025.
- According to Business Quant data, Retained Earnings over the past three periods registered $2.3 billion, -$1.4 billion, and -$8.1 million for Q4 2025, Q4 2024, and Q3 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 37.04 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 28.20 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 1.11 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 4.54 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 8.83 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | -1.81 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 18.66 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 589.60 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -2.13 Bn |
| 10 | Curaleaf Holdings | 7.13 Bn | 7.13 Bn | 157.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.35 Bn |
| Dec 31, 2024 | -1.36 Bn |
| Sep 30, 2024 | -8.05 Mn |
| Jun 30, 2024 | -15.15 Mn |
| Dec 31, 2023 | -11.88 Mn |
| Sep 30, 2023 | -1.08 Bn |
| Jun 30, 2023 | -13.86 Mn |
| Dec 31, 2022 | -18.59 Mn |
| Sep 30, 2022 | -392.06 Mn |
| Jun 30, 2022 | -338.71 Mn |
| Mar 31, 2022 | -311.38 Bn |
| Dec 31, 2021 | -489.46 Mn |
| Sep 30, 2021 | -275.61 Mn |
| Jun 30, 2021 | -219.10 Mn |
| Mar 31, 2021 | -211.86 Mn |
| Dec 31, 2020 | -190.07 Mn |
| Sep 30, 2020 | -159.37 Mn |
| Dec 31, 2019 | -132.91 Mn |